Capricor Therapeutics, Inc. · 2 months ago
MSAT Training Specialist
Capricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. As an MSAT Training Specialist, you will ensure operational excellence and GMP compliance by designing training programs, mentoring personnel, and maintaining documentation for regulatory readiness.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Develop and deliver training on GMP cell culture, cell counting, and aseptic techniques
Collaborate with subject matter experts to identify training needs and align with regulatory best practices
Mentor manufacturing personnel to foster professional growth and GMP adherence
Maintain and update SOPs, batch records, and technical documentation
Support investigations through root cause analysis, impact assessments, and CAPAs
Organize and maintain training lab, including supplies and equipment setup
Partner with QA and Manufacturing for seamless workflow integration
Support Manufacturing Operations inside an ISO7 cleanroom, including performing aseptic operations, process verification, and providing hands-on training
Qualification
Required
Bachelor's degree in life sciences or equivalent experience
1–3 years in a GMP environment, preferably in cell culture manufacturing
Strong knowledge of aseptic techniques, cell counting, and GMP production
Excellent communication, presentation, and organizational skills
Ability to work independently and collaboratively in a dynamic setting
Proficiency in documentation systems and MS Office
Company
Capricor Therapeutics, Inc.
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives.
Funding
Current Stage
Public CompanyTotal Funding
$329.5MKey Investors
Nippon ShinyakuNational Institutes of HealthCalifornia Institute for Regenerative Medicine
2025-12-05Post Ipo Equity· $150M
2024-10-17Post Ipo Equity· $75M
2024-09-17Post Ipo Equity· $15M
Recent News
2026-01-09
MarketScreener
2025-12-17
Company data provided by crunchbase